726 ésultat(s) trouvé(s)
The NECTAr platform: A pan-Canadian platform dedicated to Neonatal hypoxic-ischemic Encephalopathy — For patient Care optimization, Training, and educAtion
Aperçu du projet
At birth, some babies suffer from a condition called birth asphyxia, where their brain and organs do not receive enough oxygen or blood, leading to hypoxic-ischemic encephalopathy (HIE). This life-threatening condition is responsible for 23% of babies’ deaths worldwide and often results in cerebral palsy and difficulties with learning and…
Projet en cours
Voir le projet et les chercheursNovel biological agents in the treatment of amyotrophic lateral sclerosis based on progranulin/granulin structure
Aperçu du projet
Challenge: ALS (amyotrophic lateral sclerosis) is an incurable and invariably fatal motor neuron (MN) disease. Our challenge is to develop a biologic-therapy that slows, halts or functionally reverses ALS progression. Solution: ALS is characterized by the toxic mislocalization of a hyperphosphorylated form of TAR DNA binding protein-43 (TDP-43) within MNs.…
Projet en cours
Voir le projet et les chercheursConnecting cellular signalling data with behavioural and clinical outcomes for 5-HT receptor ligands
Aperçu du projet
The Challenge: Current therapies for treating a number of mental health disorders – depression, anxiety, and PTSD, among them – adequately treat only a small fraction of afflicted patients. Promising new targets, despite strong rationales, have not improved this picture. As ketamine provided more than two decades ago, a breakthrough…
Projet en cours
Voir le projet et les chercheursElatus: Chronically Implantable Unit-Scale Microelectrode Array Neuromodulation Technology
Aperçu du projet
Challenge: Current DRE standard of care is either DBS (Medtronic, Boston Scientific), Vagus Nerve Stimulation (VNS - Livanova) or Responsive Nerve Stimulation (RNS - NeuroPace). These devices rarely eliminate seizures, and there is little to differentiate them from one another. Typically, median seizure reduction is 50-70% which, while statistically significant,…
Projet en cours
Voir le projet et les chercheursA brain-specific approach to RNA therapeutics: developing a novel protein delivery strategy for the central nervous system
Aperçu du projet
Challenge: Delivery of therapeutic proteins to the brain has been a longstanding barrier to CNS drug development. Protein replacement or supplementation strategies hold promise for multiple brain diseases, from enzyme-replacement for neuronopathic lysosomal disorders, to growth factor supplementation for neurodegeneration, to cytokine immunotherapy for brain cancers. However, most brain diseases…